Evidence syntheses — page 5
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
Reviews
-
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate18 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate13 Feb 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate18 Apr 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate02 Jun 2026 -
In the population defined for obesity and overweight in adults, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate09 Nov 2024 -
In the population defined for obesity and overweight in adults, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate04 Feb 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its comparator?
Moderate16 Jun 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide, oral maintained across the full duration of the contributing trials?
High06 Aug 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide, oral compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High18 Jan 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its comparator?
High19 May 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, is the effect of Teduglutide maintained across the full duration of the contributing trials?
Moderate22 Nov 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Teduglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate28 Jun 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with Teduglutide compared with its comparator?
Moderate07 Sep 2026 -
In the population defined for cutaneous wound healing and tissue repair, is the effect of Thymosin beta-4 maintained across the full duration of the contributing trials?
Low10 Mar 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of Thymosin beta-4 compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low10 Jun 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with Thymosin beta-4 compared with its comparator?
Low24 Jul 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the contributing trials?
Moderate02 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate20 Nov 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide) compared with its comparator?
Moderate12 Jun 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, is the effect of CJC-1295 maintained across the full duration of the contributing trials?
Low07 Mar 2026
page 5 of 7